Palvella Therapeutics to Present at the Jones Healthcare and Technology Innovation Conference
Rhea-AI Summary
Palvella Therapeutics (Nasdaq: PVLA), a clinical-stage biopharmaceutical company specializing in treatments for rare genetic skin diseases, has announced its upcoming participation in the Jones Healthcare and Technology Innovation Conference.
The company's Founder and CEO, Wes Kaupinen, will engage in a fireside chat on Wednesday, April 9, 2025, at 2:00 p.m. PT. The presentation will be accessible through a live webcast on the Events and Presentations section of Palvella's website (www.palvellatx.com), with the replay remaining available for approximately 90 days afterward.
Palvella focuses on developing novel therapies for serious rare genetic skin conditions that currently lack FDA-approved treatments.
Positive
- None.
Negative
- None.
News Market Reaction – PVLA
In the trading session that priced this news, PVLA declined 1.84%, reflecting a mild negative market reaction.
Data tracked by StockTitan Argus on the day of publication.
AI-generated analysis. How Rhea-AI works. Not financial advice.
WAYNE, Pa., April 04, 2025 (GLOBE NEWSWIRE) -- (Nasdaq: PVLA) Palvella Therapeutics, Inc. (Palvella), a clinical-stage biopharmaceutical company focused on developing and commercializing novel therapies to treat patients suffering from serious, rare genetic skin diseases for which there are no Food and Drug Administration (FDA)-approved therapies, today announced that Wes Kaupinen, Founder and Chief Executive Officer of Palvella will participate in a fireside chat at the Jones Healthcare and Technology Innovation Conference on Wednesday, April 9, 2025, at 2:00 p.m. PT.
A live webcast of the fireside chat will be available on the Events and Presentations section of Palvella's website at www.palvellatx.com. An archived replay of the webcast will be available for approximately 90 days following the presentation.
About Palvella Therapeutics
Founded and led by rare disease drug development veterans, Palvella Therapeutics, Inc. (Nasdaq: PVLA) is a clinical-stage biopharmaceutical company focused on developing and commercializing novel therapies to treat patients suffering from serious, rare genetic skin diseases for which there are no FDA-approved therapies. Palvella is developing a broad pipeline of product candidates based on its patented QTORIN™ platform, with an initial focus on serious, rare genetic skin diseases, many of which are lifelong in nature. Palvella’s lead product candidate, QTORIN
QTORIN™ rapamycin is for investigational use only and has not been approved or cleared by the FDA or by any other regulatory agency for any indication.
Contact Information
Investors
Wesley H. Kaupinen
Founder and CEO, Palvella Therapeutics
wes.kaupinen@palvellatx.com
Media
Marcy Nanus
Managing Partner, Trilon Advisors, LLC
mnanus@trilonadvisors.com
